Recent Updates
Recently added Catalysts
ACET Neutral Sentiment

Adicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare Conference

Key Takeaway: Adicet Bio is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference. This event will provide an opportunity for the company to discuss its strategies and developments in the biopharma sector. Further details regarding the timing and specific topics of discussion have not been disclosed.
Price reaction · baseline $8.07 (2026-05-13 close) · hit after-hours · clean, no other ACET news in the window
day 0 close · peak
+4.2%

Conference Participation Details

Jefferies Global Healthcare Conference
Date: November 18, 2025
Time: 11:30 a.m. GMT / 6:30 a.m. ET
Location: London
Format: Fireside Chat

How to Access

Investors and the general public can listen to both sessions live at:

https://investor.viatris.com

Archived versions will be available following the live events for a limited time.

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~17 mo
Low dilution risk
Lead asset
ADI-001
Phase 1 · Lupus Nephritis

Full Press Release Details

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference being held from June 2-4, 2026 in New York.
Details of the event are as follows:Date: Thursday, June 4, 2026Time: 7:35a.m. ET
The live audio webcast can be accessed on the Investors section of Adicet Bio’s website athttp://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website athttps://www.adicetbio.com.
Last updated: May 14, 2026